DNAtrix Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 11

DNAtrix General Information

Description

Operator of a biotechnology company intended to focus on the development of oncolytic virus technology for the treatment of cancer. The company's immunotherapies consist of a conditionally replicative oncolytic virus that eliminates cancer by directly killing cancer cells, awakening the immune system, and driving an immune response against tumors, enabling healthcare professionals to augment a patient's immune system.

Contact Information

Website
www.dnatrixinc.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2450 Holcombe Boulevard
  • Houston, TX 77021
  • United States
+1 (713)
Primary Industry
Biotechnology
Other Industries
Decision/Risk Analysis
Drug Discovery
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 2450 Holcombe Boulevard
  • Houston, TX 77021
  • United States
+1 (713)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DNAtrix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Secondary Transaction - Private 01-Feb-2026 Completed Clinical Trials - Phase 3
11. Grant 01-Sep-2022 Completed Clinical Trials - Phase 3
10. Debt - PPP 14-Apr-2020 Completed Clinical Trials - Phase 3
9. Grant 31-Dec-2018 Completed Clinical Trials - Phase 3
8. Later Stage VC (Series C) 24-Sep-2018 Completed Clinical Trials - Phase 3
7. Accelerator/Incubator 31-Aug-2016 Completed Clinical Trials - Phase 3
6. Grant 04-Aug-2016 Completed Clinical Trials - Phase 3
5. Later Stage VC (Series B) 14-Oct-2014 Completed Clinical Trials - Phase 3
4. Grant 24-Feb-2014 $10.8M $2.73M Completed Clinical Trials - Phase 3
3. Later Stage VC (Series A1) 27-Aug-2013 $1.73M $2.73M Completed Clinical Trials - Phase 3
To view DNAtrix’s complete valuation and funding history, request access »

DNAtrix Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C
Series B
Series A1 500,291 $0.010000 $0.68 $8.5 $8.5 1x $8.5 14.17%
Series A 120,822 $0.010000 $0.43 $5.41 $5.41 1x $5.41 3.42%
To view DNAtrix’s complete cap table history, request access »

DNAtrix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to focus on the development of oncolytic virus technology for the treatment
Biotechnology
Houston, TX
13 As of 2022

Rum, Austria
 

Cambridge, MA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DNAtrix Competitors (70)

One of DNAtrix’s 70 competitors is ViraTherapeutics, a Formerly VC-backed company based in Rum, Austria.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ViraTherapeutics Formerly VC-backed Rum, Austria
AnTolRx Formerly VC-backed Cambridge, MA
Senti Biosciences Holdings Formerly VC-backed South San Francisco, CA
Replimune Formerly VC-backed Woburn, MA
Seneca Therapeutics Venture Capital-Backed Blue Bell, PA
You’re viewing 5 of 70 competitors. Get the full list »

DNAtrix Patents

  • 60

    Total Documents Applications and Grants

  • Total Patents Families

  • 18

    Granted

  • 10

    Pending

  • Expiring in next 12 mo

DNAtrix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4329878-A1 Use of oncolytic adenovirus for the treatment of pediatric brain cancer Pending 26-Apr-2021
EP-4329878-A4 Use of oncolytic adenovirus for the treatment of pediatric brain cancer Pending 26-Apr-2021
US-20240216492-A1 Use of oncolytic adenovirus for the treatment of pediatric brain cancer Pending 26-Apr-2021
WO-2022232176-A1 Use of oncolytic adenovirus for the treatment of pediatric brain cancer Inactive 26-Apr-2021
AU-2017379835-A1 Armed replication-competent oncolytic adenoviruses Inactive 21-Dec-2016 A61K48/0058
To view DNAtrix’s complete patent history, request access »

DNAtrix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DNAtrix Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
U.S. Department of Health and Human Services Government
5Y Capital Venture Capital Minority
GOOSE Capital Venture Capital Minority
Houston Angel Network Angel Group Minority
Johnson & Johnson Innovation - JLABS Accelerator/Incubator Minority
You’re viewing 5 of 11 investors. Get the full list »

DNAtrix Acquisitions (1)

DNAtrix’s most recent deal was a Merger/Acquisition with VectorLogics. The deal was made on 23-Oct-2012.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
VectorLogics 23-Oct-2012 Merger/Acquisition Drug Discovery
To view DNAtrix’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

DNAtrix FAQs

  • When was DNAtrix founded?

    DNAtrix was founded in 2005.

  • Where is DNAtrix headquartered?

    DNAtrix is headquartered in Houston, TX.

  • What is the size of DNAtrix?

    DNAtrix has 13 total employees.

  • What industry is DNAtrix in?

    DNAtrix’s primary industry is Biotechnology.

  • Is DNAtrix a private or public company?

    DNAtrix is a Private company.

  • What is DNAtrix’s current revenue?

    The current revenue for DNAtrix is .

  • How much funding has DNAtrix raised over time?

    DNAtrix has raised $38.1M.

  • Who are DNAtrix’s investors?

    U.S. Department of Health and Human Services, 5Y Capital, GOOSE Capital, Houston Angel Network, and Johnson & Johnson Innovation - JLABS are 5 of 11 investors who have invested in DNAtrix.

  • Who are DNAtrix’s competitors?

    ViraTherapeutics, AnTolRx, Senti Biosciences Holdings, Replimune, and Seneca Therapeutics are some of the 70 competitors of DNAtrix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process